Diwakar Jain, MD
Nuclear Cardiology · Hawthorne, NYNPI 1265480784
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,534 of the $104,856 with a category attached, or 81.6%. Astellas Pharma US Inc accounts for 66.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $55,488 and has fallen 81.2% since, to $10,449 in 2025. Among nuclear cardiology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $1248.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$70K
- Pfizer$34K
- E.r. Squibb & Sons, L.L.C.$228
- Novo Nordisk$125
- Boehringer Ingelheim$123
- Eisai Inc.$50
- plus $48 from 2 others
Across 57 payments — averaging $2421.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$78K
- Janssen Research & Development, LLC$33K
- Amgen$17K
- GE HealthCare$10K
What the payments were for
- Consulting fees$4,5504%
- Speaking & faculty fees$85,53482%
- Travel & lodging$12,72612%
- Food & beverage$2,0462%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 51 | $69,814 |
| Pfizer | 26 | $34,468 |
| E.r. Squibb & Sons, L.L.C. | 2 | $228 |
| Novo Nordisk | 1 | $125 |
| Boehringer Ingelheim | 1 | $123 |
| Eisai Inc. | 1 | $50 |
| GE HealthCare | 1 | $31 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,856 in reported general payments places this provider in the 95th percentile of 21 nuclear cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $31,378 |
| XareltoRivaroxaban | 15 | $24,358 |
| Valsartan | 22 | $848 |
| Metoprolol Succinate | 46 | $753 |
| Rosuvastatin Calcium | 45 | $498 |
| Losartan Potassium | 33 | $456 |
| Amlodipine Besylate | 35 | $385 |
| Lisinopril | 24 | $364 |
| Atorvastatin Calcium | 52 | $336 |
| Metoprolol Tartrate | 29 | $297 |
| Carvedilol | 35 | $272 |
| Hydrochlorothiazide | 52 | $225 |
| ClopidogrelClopidogrel Bisulfate | 19 | $188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34,468 | $31,37822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 nuclear cardiology providers in New York.
Other nuclear cardiology in Hawthorne
- Klaus RentropNew York$5.6M
- John AsheldWest Islip$24K
- Brian RiegelWilliamsville$23K
- Wilbur AsheldWest Islip$11K
- Jonathan WeinsaftNew York$10K
- Ossama SamuelBrooklyn$7K
- Rajesh RohatgiGarden City$4K
- Harout YacoubNew York$2K
- Nicholas PapapietroBrooklyn$2K
- Ahmad Nawid LatifiRochester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.